Literature DB >> 21642659

Syringoid eccrine carcinoma: a clinicopathological and immunohistochemical study of four cases.

M Sidiropoulos1, S Sade, A Al-Habeeb, D Ghazarian.   

Abstract

BACKGROUND: Syringoid eccrine carcinoma (SEC) is a rare malignant adnexal tumour with variable presentations. AIM: To examine the clinicopathological and immunohistochemical features of SEC.
METHODS: Four cases were reviewed by three dermatopathologists and the immunohistochemical profile was examined using antibodies against CK5/6, CK7, CK14, CK20, LMWK, HMWK, EMA, mCEA, p63, ER, PR, AR, S-100 and Ber-EP4.
RESULTS: The cases occurred in two men and two women, ranging in age from 61 to 87 years (mean 68.5). Two of the lesions were from the face and two from the trunk. All four lesions were composed of an atypical infiltrative mass with syringoma-like tadpole morphology with ductular differentiation and prominent desmoplasia. Three cases demonstrated perineural invasion and two had positive lymph node metastases. Immunostaining was variable. Immunohistochemistry positivity was as follows: three out of four cases were positive for CK5/6, CK7 (2/4), CK14 (1/3), CK20 (0/2), HMWK (0/2), LMWK (1/2), EMA (3/4), mCEA (4/4), p63 (2/3), ER (2/3), PR (1/2), AR (0/3), S-100 (0/3) and Ber-EP4 (2/2).
CONCLUSION: SEC can present on the trunk and are not limited to the head and neck region. In addition to syringoma-like tadpole structures and glandular differentiation, these tumours can also exhibit squamoid and cribriform growth patterns. Immunostaining in SEC is variable and this variability is believed to stem from this tumour's ability to differentiate along multiple routes, including sweat secretory and/or ductal differentiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642659     DOI: 10.1136/jclinpath-2011-200069

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Syringoid eccrine carcinoma of the eyelid presenting as cicatricial entropion.

Authors:  Manjool M Shah; Eric A Steele; Kevin P White; David J Wilson
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

2.  Occurrence of 2 Primary Rare Tumors on the Scalp of a 43-Year-Old Woman.

Authors:  Clarissa Mitri Espanhol; Manoella Freitas Santos; Claurio Roncuni Ferreira; Roque Domingos Furian; Virgílio Zanella; Leandro Damiani
Journal:  Skin Appendage Disord       Date:  2019-09-24

3.  Microcystic adnexal carcinoma of the cheek-a case report with dermatoscopy and dermatopathology.

Authors:  Mike Inskip; Jill Magee
Journal:  Dermatol Pract Concept       Date:  2015-01-30

4.  Syringoid Eccrine Carcinoma of the Thigh.

Authors:  Yong-Yon Won; Dong-Woo Suh; Bark-Lynn Lew; Woo-Young Sim
Journal:  Ann Dermatol       Date:  2017-10-30       Impact factor: 1.444

5.  Ductal eccrine carcinoma of the axilla: a diagnostic pitfall.

Authors:  Maria Helena Toda Sanches de Brito; Cecília Silva Nunes de Moura Dionísio; Joana Cintia Monteiro Ferreira; Maria Joaninha Madalena de Palma Mendonça da Costa Rosa; Fernando Petrucci Bernardo E Cunha; Maria Manuela Antunes Pecegueiro da Silva Garcia
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

Review 6.  Syringoid Eccrine Carcinoma in the Abdominal Wall: A Rare Case Report and Literature Review.

Authors:  Miguel Augusto Pereira; Luciana Pantaleão; Mayra Rochael
Journal:  Am J Case Rep       Date:  2019-12-19

7.  Rare syringoid eccrine carcinoma of the upper lip and nasal base treated with resection and subsequent innovative reconstruction using an Abbé flap, turbinate flaps and three-stage forehead flap: a case report.

Authors:  Zdeněk Dvořák; Richard Pink; Petr Heinz; Jaroslav Michálek; Petr Krsička
Journal:  World J Surg Oncol       Date:  2022-09-08       Impact factor: 3.253

8.  Metastatic syringoid eccrine carcinoma of the nipple.

Authors:  Pierluigi Ballardini; Guido Margutti; Massimo Pedriali; Patrizia Querzoli
Journal:  Int Med Case Rep J       Date:  2012-07-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.